Autologous Adipose Derived Mesenchymal Cells(Regeneris Medical)(Autologous Adipose Derived Mesenchymal Cells(Regeneris Medical))

概要

基本信息

药物类型

间充质干细胞疗法

别名

Autologous Adipose MSC's(Regeneris Medical)

靶点-

作用方式-

作用机制-

治疗领域

感染呼吸系统疾病

在研适应症

新型冠状病毒感染

非在研适应症-

原研机构

Regeneris Medical

在研机构

Regeneris Medical

非在研机构-

权益机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

1

项与 Autologous Adipose Derived Mesenchymal Cells(Regeneris Medical) 相关的临床试验

NCT04352803

/ Not yet recruiting临床1期

IV Infusion of Autologous Adipose Derived Mesenchymal Cells for Abatement of Respiratory Compromise in SARS-CoV-2 Pandemic (COVID-19)

The aim of this study is to evaluate the safety and efficacy of autologous adipose-derived mesenchymal cells for treating confirmed or suspected patients with SARS-CoV-2 and compromised respiratory function requiring hospitalization.
The hypothesis of the Study is autologous adipose-derived mesenchymal cells given IV to eligible patients will improve clinical outcomes of COVID 19 positive patients with severe pneumonia or ARDS by reducing or avoiding cytokine storm.

开始日期2020-04-01

申办/合作机构

Regeneris Medical

100 项与 Autologous Adipose Derived Mesenchymal Cells(Regeneris Medical) 相关的临床结果

登录后查看更多信息

100 项与 Autologous Adipose Derived Mesenchymal Cells(Regeneris Medical) 相关的转化医学

登录后查看更多信息

100 项与 Autologous Adipose Derived Mesenchymal Cells(Regeneris Medical) 相关的专利（医药）

登录后查看更多信息

100 项与 Autologous Adipose Derived Mesenchymal Cells(Regeneris Medical) 相关的药物交易

登录后查看更多信息